1.High levels of soluble herpes virus entry mediator in sera of patients with allergic and autoimmune diseases.
Hyo Won JUNG ; Su Jin LA ; Ji Young KIM ; Suk Kyeung HEO ; Ju Yang KIM ; Sa WANG ; Kack Kyun KIM ; Ki Man LEE ; Hong Rae CHO ; Hyeon Woo LEE ; Byungsuk KWON ; Byung Sam KIM ; Byoung Se KWON
Experimental & Molecular Medicine 2003;35(6):501-508
Herpes virus entry mediator (HVEM) is a newly discovered member of the tumor necrosis factor receptor (TNFR) superfamily that has a role in herpes simplex virus entry, in T cell activation and in tumor immunity. We generated mAb against HVEM and detected soluble HVEM (SHVEM) in the sera of patients with various autoimmune diseases. HVEM was constitutively expressed on CD4(+)and CD8(+)T cells, CD19(+)B cells, CD14(+)monocytes, neutrophils and dendritic cells. In three-way MLR, mAb 122 and 139 were agonists and mAb 108 had blocking activity. An ELISA was developed to detect sHVEM in patient sera. sHVEM levels were elevated in sera of patients with allergic asthma, atopic dermatitis and rheumatoid arthritis. The mAbs discussed here may be useful for studies of the role of HVEM in immune responses. Detection of soluble HVEM might have diagnostic and prognostic value in certain immunological disorders.
Animals
;
Antibodies, Monoclonal/immunology
;
Antibody Specificity
;
Arthritis, Rheumatoid/blood/immunology
;
Asthma/blood/immunology
;
Autoimmune Diseases/*blood/immunology
;
Cell Division
;
Cell Line
;
Dermatitis, Atopic/blood/immunology
;
Female
;
Flow Cytometry
;
Humans
;
Hypersensitivity/*blood/immunology
;
Lymphocyte Culture Test, Mixed
;
Mice
;
Mice, Inbred BALB C
;
Receptors, Tumor Necrosis Factor/*blood/immunology
;
Receptors, Tumor Necrosis Factor, Member 14
;
Receptors, Virus/*blood/immunology
;
Solubility
2.Expression of Galectin-9 and Tim-3 in lungs of mice with asthma.
Zhi-Ying ZHANG ; Bin LUAN ; Xiao-Xia FENG
Chinese Journal of Contemporary Pediatrics 2011;13(5):406-410
OBJECTIVETo study the expression of Galectin-9 and Tim-3 in lungs of mice with asthma and the effect of rosiglitazone (PPAR-γ agonist) on their expression.
METHODSFortyfive BALB/c SPF female mice were randomized into control group and asthma groups with and without rosiglitazone intervention. After ovalbumin stimulation and rosiglitazone intervention the pathological changes of the lung tissues were observed. Galectin-9 and Tim-3 mRNA levels in lung tissues were determined using RT-PCR. The levels of IL-4 and IFN-γ in peripheral blood were measured using ELISA.
RESULTSThe expression of Galectin-9 and Tim-3 mRNA of lung tissues in the untreated asthma group increased significantly compared with the control and the rosiglitazone treated groups (P<0.05). A significantly increased blood expression of IL-4 and a significantly decreased blood expression of IFN-γ were found in the untreated asthma group compared with the control and the rosiglitazone-treated groups (P<0.05). The expression of Galectin-9 and Tim-3 mRNA was positively correlated with blood IL-4 level (r=0.792, r=0.794 respectively; P<0.05), but negatively correlated with blood IFN-γ level (r=-0.692, r=-0.757 respectively; P<0.05).
CONCLUSIONSGalectin-9 and Tim-3 mRNA levels in lungs increase in mice with asthma and significantly correlate with the levels of blood Th1/Th2 cytokines. This suggests that Galectin-9 and Tim-3 are closely related to inflammatory process in asthma. Rosiglitazone treatment may decrease the expression of Galectin-9 and Tim-3.
Animals ; Asthma ; drug therapy ; immunology ; pathology ; Female ; Galectins ; genetics ; Hepatitis A Virus Cellular Receptor 2 ; Interferon-gamma ; blood ; Interleukin-4 ; blood ; Lung ; metabolism ; pathology ; Mice ; Mice, Inbred BALB C ; PPAR gamma ; physiology ; RNA, Messenger ; analysis ; Receptors, Virus ; genetics ; Reverse Transcriptase Polymerase Chain Reaction ; Th1 Cells ; immunology ; Th2 Cells ; immunology ; Thiazolidinediones ; therapeutic use